Invex Completes $900,000 Placement, Advances $10 Million Rekover Funding Plan
IXC: $0.100 +0.00% · MC: $8M
Invex Therapeutics issued shares to raise $900,000, completing the committed first tranche of its previously announced placement; the larger remaining tranche is still subject to shareholder approval, and the combined raise is intended principally to fund the planned Rekover study and ongoing Exenatide development. The quarter ended with $4 million in cash, down from $4 million in the prior quarter, while operating cash outflows eased to $425,000 from $501,000.

Comments